Literature DB >> 23404267

[Long-term use of proton pump inhibitors: who needs prophylaxis?].

M Scheurlen1.   

Abstract

Proton pump inhibitors (PPI) are among the most frequently prescribed drugs worldwide. Recently, several side effects of chronic PPI therapy have been identified. Reduced intestinal absorption of vitamin B12 or calcium, an increased rate of bone fractures, an interference with the metabolism of other drugs (e.g., clopidogrel), and an increased incidence of Clostridium difficile-associated colitis are discussed. So far, data on such side effects of PPI are mainly supported by retrospective and/or uncontrolled studies. Therefore, a definitive estimation of the real risk of long-term PPI medication is not yet possible. However, since chronic treatment with PPI may lead to severe side effects, it is necessary to keep the established indications for these drugs (peptic ulcer therapy, gastro-esophageal reflux disease, prophylaxis of mucosal lesions by potentially ulcerogenic drugs) in mind. PPI therapy as stress ulcer prophylaxis should be confined to risk groups and risk situations. Long-term treatment with PPI requires repeated confirmation of a persisting indication, choice of the lowest effective dose, and-if applicable-an interval or "on demand" treatment.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23404267     DOI: 10.1007/s00108-012-3231-2

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

1.  Clopidogrel with or without omeprazole in coronary artery disease.

Authors:  Deepak L Bhatt; Byron L Cryer; Charles F Contant; Marc Cohen; Angel Lanas; Thomas J Schnitzer; Thomas L Shook; Pablo Lapuerta; Mark A Goldsmith; Loren Laine; Benjamin M Scirica; Sabina A Murphy; Christopher P Cannon
Journal:  N Engl J Med       Date:  2010-10-06       Impact factor: 91.245

2.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection.

Authors:  Michael D Howell; Victor Novack; Philip Grgurich; Diane Soulliard; Lena Novack; Michael Pencina; Daniel Talmor
Journal:  Arch Intern Med       Date:  2010-05-10

Review 3.  ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use.

Authors:  Neena S Abraham; Mark A Hlatky; Elliott M Antman; Deepak L Bhatt; David J Bjorkman; Craig B Clark; Curt D Furberg; David A Johnson; Charles J Kahi; Loren Laine; Kenneth W Mahaffey; Eamonn M Quigley; James Scheiman; Laurence S Sperling; Gordon F Tomaselli
Journal:  Am J Gastroenterol       Date:  2010-12       Impact factor: 10.864

Review 4.  [New aspects on "triple therapy" after coronary stent implantation].

Authors:  Axel Schlitt
Journal:  Dtsch Med Wochenschr       Date:  2010-10-05       Impact factor: 0.628

5.  Meta-analysis: risk of fractures with acid-suppressing medication.

Authors:  Chun Shing Kwok; Jessica Ka-Yan Yeong; Yoon Kong Loke
Journal:  Bone       Date:  2010-12-23       Impact factor: 4.398

6.  Appropriateness of proton pump inhibitor recommendations at hospital discharge and continuation in primary care.

Authors:  D Ahrens; G Behrens; W Himmel; M M Kochen; J-F Chenot
Journal:  Int J Clin Pract       Date:  2012-08       Impact factor: 2.503

Review 7.  Adverse effects of long-term proton pump inhibitor therapy.

Authors:  Edward Sheen; George Triadafilopoulos
Journal:  Dig Dis Sci       Date:  2011-03-02       Impact factor: 3.199

8.  [Evidence-based management of ST-segment elevation myocardial infarction (STEMI). Latest guidelines of the European Society of Cardiology (ESC) 2010].

Authors:  S Silber
Journal:  Herz       Date:  2010-12       Impact factor: 1.443

Review 9.  Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected].

Authors:  Joel J Heidelbaugh; Kathleen L Goldberg; John M Inadomi
Journal:  Am J Gastroenterol       Date:  2009-03       Impact factor: 10.864

10.  Severe hypomagnesaemia in long-term users of proton-pump inhibitors.

Authors:  T Cundy; A Dissanayake
Journal:  Clin Endocrinol (Oxf)       Date:  2008-01-23       Impact factor: 3.478

View more
  2 in total

1.  [A 78-year-old female patient with dizziness, apraxia and seizure under proton pump inhibitor therapy].

Authors:  V Piezzi; G A Kullak-Ublick; P Glisenti
Journal:  Internist (Berl)       Date:  2014-02       Impact factor: 0.743

2.  [Pain management in elderly patients].

Authors:  F Luttosch; C Baerwald
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.